Thank you to Madrigal for sponsoring this FAQ Video Module.
In this GHAPP FAQ Video Module, Jonathan Yeh, a physician assistant at the Center for Liver Disease and Transplantation at Columbia University Irving Medical Center, discusses advancements in diagnosing and staging metabolic dysfunction-associated steatohepatitis (MASH). He explains the transition from traditional liver biopsy to non-invasive testing methods such as FibroScan and the Enhanced Liver Fibrosis (ELF) test for assessing fibrosis stages. Jonathan highlights the use of these methods, in combination with blood tests, to provide reliable staging of fibrosis in patients with MASH.
Related Podcast

Part 4 - MASH- What We Don't Know, What We Want to Know
2024

Key Takeaways - Major Advancements In The Management of MASH with Parvez, Mantry, MD
2024

Part 3 - Strategies for Educating the APP Community on MASH
2024

What Is Resmetirom and How Does It Work to Treat MASH?
2025

What is MASH?
2025

What Is the Clinical Profile of Resmetirom, Including Dosing Schedules?
2025

GHAPPcast: Recognizing the Severity of MASH
2025

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2025

What Are the Consequences of MASH Going Untreated?
2025

Part 1 - Incorporating the Newly Approved Therapy for MASH into Practice
2024